John Maxwell is Chief Financial Officer at Wejo, responsible for delivering strong financial results through revenue growth and cost management, capital markets transactions, investor relations and board management.
John comes to Wejo with more than 30 years of experience driving financial growth in highly successful start-ups in complex industries including tech and telecom. Most recently, he was CFO of Aquestive Therapeutics (Nasdaq: AQST), a specialty pharmaceutical company with a focus on epilepsy and allergy treatments. During his four-year tenure at the company, he prepared AQST for its IPO, raising $115 million of new equity capital in its 2018 IPO and 2019 follow-on. John also led a $100 million debt recapitalization and $125 million royalty monetization transaction at Aquestive. Before that he served as SVP of finance and administration at PanAmSat (NYSE: PA), which he helped take private, and subsequently brought public in 2005. He was also CFO at private equity-backed WIL Research, which was acquired by Charles River Laboratories in 2016. Maxwell started his career at Ernst & Young, and held various senior financial roles at General Signal, ADP, INFONXX and Plainfield Asset Management.
John earned his MBA in Finance and International Business from NYU’s Stern School of Business and received his BBA in Accounting from Texas Tech University. He is a Certified Public Accountant.